EGFR and non-small cell lung carcinoma: FMN was found to have the potential to become a new EGFR inhibitor and show a significant inhibitory effect on both osimertinib-sensitive and resistant non-small cell lung cancer cells, which could greatly reduce the generation of drug resistance (Yu et al., 2020).